CAPSTONE THERAPEUTICS CORP. WARRANT TO PURCHASE COMMON STOCKWarrant Agreement • February 5th, 2018 • Delaware
Contract Type FiledFebruary 5th, 2018 JurisdictionTHIS CERTIFIES THAT, for value received, the receipt and sufficiency of which are hereby acknowledged, BP Peptides, LLC, a Delaware limited liability company, or its registered assigns (as the case may be, the “Holder”), is entitled, subject to the terms and conditions set forth herein, to purchase from Capstone Therapeutics Corp., a Delaware corporation (the “Company”), up to six million, three hundred and twenty-one thousand, nine hundred and thirty (6,321,930) (the “Warrant Number”) duly authorized, validly issued, fully-paid and non-assessable shares (the “Warrant Shares”) of the Company’s Common Stock, par value $.0005 per share (the “Warrant Stock”), subject to adjustment as provided herein, at a purchase price equal to $.075 per share (the “Exercise Price”), subject to adjustment as provided herein. The term “Warrant” as used herein shall mean this warrant, and any warrants delivered in substitution or exchange therefor as provided herein.